Novo Nordisk A/S Slogs Through the Year
Novo Nordisk (NYSE: NVO) continues to slog through the year, dealing with losing exclusivity on hormone-replacement therapy Vagifem and pricing pressure. The year-over-year comparison for Vagifem will go away, but expect continued pricing pressure next year. Fortunately Novo Nordisk has an opportunity to launch semaglutide; that will likely end up being its top-selling drug, and should make up for the lower prices.
Metric
First 9 Months 2017
Source: Fool.com
Novo Nordisk A/S ADR Stock
€105.00
0.000%
With 25 Buy predictions and 1 Sell predictions Novo Nordisk A/S ADR is one of the favorites of our community.
With a target price of 144 € there is a positive potential of 37.14% for Novo Nordisk A/S ADR compared to the current price of 105.0 €.
